“We are deeply disappointed that CMS passed on addressing the issue of copay assistance for prescription drugs and requiring insurers and pharmacy benefit managers (PBMs) to count assistance towards patient out-of-pocket cost-sharing and deductibles,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Washington DC… Today, the Trump administration rushed out the partial release of the rules that govern how private health plans must operate in 2022 and in doing so…
Washington DC… In a victory for patients’ ability to afford prescription drugs, the Trump administration has delayed for two years implementation of a provision included in a proposed…
Washington DC…In a setback to patients’ ability to afford prescription drugs, the Trump administration has again attacked the use of drug manufacturer copay assistance for prescription…
Washington DC…Today, in a shock to patients, the Trump administration announced that health insurers do not have to count copay assistance from drug manufacturers towards…